{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:31Z","timestamp":1790695051849,"version":"4.1.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.2337\/dci19-0008","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T20:25:28Z","timestamp":1558383928000},"page":"991-993","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":44,"title":["SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-6758","authenticated-orcid":false,"given":"Joseph I.","family":"Wolfsdorf","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Boston Children\u2019s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Ratner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Georgetown University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"2022031300022241900_B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D Exchange in 2016\u20132018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"2022031300022241900_B2","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc19-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B3","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300022241900_B4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.15585\/mmwr.mm6712a3","article-title":"Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality\u2014United States, 2000\u20132014","volume":"67","author":"Benoit","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022031300022241900_B5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.2337\/dc17-0403","article-title":"Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D Exchange registries","volume":"40","author":"Lyons","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300022241900_B7","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B9","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes","volume":"40","author":"Rodbard","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B11","unstructured":"Astellas Pharma. Approval of Suglat tablets, selective SGLT2 inhibitor, for additional indication of type 1 diabetes mellitus and additional dosage and administration in Japan. Press release [Internet], 2018. Available from https:\/\/www.astellas.com\/en\/news\/14481. Accessed 20 February 2019"},{"key":"2022031300022241900_B12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300022241900_B13","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium\u2013glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/dia.2017.0267","article-title":"Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study","volume":"19","author":"Patel","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"2022031300022241900_B16","unstructured":"U.S. Food and Drug Administration. 2019 Meeting Materials, January 17, 2019 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee [Internet]. Available from https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm627276.htm. Accessed 24 February 2019"},{"key":"2022031300022241900_B17"},{"key":"2022031300022241900_B18","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.2337\/dc16-2620","article-title":"Poor adherence to ketone testing in patients with type 1 diabetes","volume":"40","author":"Albanese-O\u2019Neill","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2337\/dci18-0004","article-title":"Increasing hospitalizations for DKA: a need for prevention programs","volume":"41","author":"Vellanki","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300022241900_B20"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/991\/553032\/dci190008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/991\/553032\/dci190008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:02:54Z","timestamp":1647122574000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/6\/991\/36067\/SGLT-Inhibitors-for-Type-1-Diabetes-Proceed-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,5,10]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci19-0008","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]}}}